Overweight Clinical Trials in Dallas, Texas
23 recruitingDallas, Texas
Showing 1–20 of 23 trials
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company1,217 enrolled53 locationsNCT06143956
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Type 2 Diabetes Mellitus (T2DM)Obese or Overweight Healthy Volunteers
Alnylam Pharmaceuticals144 enrolled20 locationsNCT06845202
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
PsoriasisOverweight or Obesity
Eli Lilly and Company200 enrolled43 locationsNCT06857942
Recruiting
Phase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
ObesityHealthyOverweight+1 more
Eli Lilly and Company216 enrolled6 locationsNCT06945419
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Chronic Low Back Pain (CLBP)ObesityOverweight
Eli Lilly and Company586 enrolled41 locationsNCT07035093
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Not Applicable
Comparing Outcomes Among Children With Obesity in a Community Healthy Lifestyle Program
Pediatric ObesityPediatric Overweight
University of Texas Southwestern Medical Center160 enrolled1 locationNCT07342855
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company250 enrolled31 locationsNCT07232719
Recruiting
Phase 1
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
ObesityHealthyOverweight
Eli Lilly and Company120 enrolled3 locationsNCT07232732
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472
Recruiting
Healthy Living BEYOND Weight Study
Overweight or Obesity
American Heart Association1,000,000 enrolled1 locationNCT07075341